[go: up one dir, main page]

WO2018096525A3 - Heteroaryl compounds and uses thereof - Google Patents

Heteroaryl compounds and uses thereof Download PDF

Info

Publication number
WO2018096525A3
WO2018096525A3 PCT/IB2018/052089 IB2018052089W WO2018096525A3 WO 2018096525 A3 WO2018096525 A3 WO 2018096525A3 IB 2018052089 W IB2018052089 W IB 2018052089W WO 2018096525 A3 WO2018096525 A3 WO 2018096525A3
Authority
WO
WIPO (PCT)
Prior art keywords
heteroaryl compounds
compounds
methods
pharmaceutically acceptable
heteroaryl
Prior art date
Application number
PCT/IB2018/052089
Other languages
French (fr)
Other versions
WO2018096525A2 (en
Inventor
Peter Anthony CICALA
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Priority to PCT/IB2018/052089 priority Critical patent/WO2018096525A2/en
Publication of WO2018096525A2 publication Critical patent/WO2018096525A2/en
Publication of WO2018096525A3 publication Critical patent/WO2018096525A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
PCT/IB2018/052089 2018-03-27 2018-03-27 Heteroaryl compounds and uses thereof WO2018096525A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/052089 WO2018096525A2 (en) 2018-03-27 2018-03-27 Heteroaryl compounds and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/052089 WO2018096525A2 (en) 2018-03-27 2018-03-27 Heteroaryl compounds and uses thereof

Publications (2)

Publication Number Publication Date
WO2018096525A2 WO2018096525A2 (en) 2018-05-31
WO2018096525A3 true WO2018096525A3 (en) 2018-09-27

Family

ID=62195457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/052089 WO2018096525A2 (en) 2018-03-27 2018-03-27 Heteroaryl compounds and uses thereof

Country Status (1)

Country Link
WO (1) WO2018096525A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140953A1 (en) * 2018-01-16 2019-07-25 深圳市塔吉瑞生物医药有限公司 Diphenylaminopyrimidine compound for inhibiting kinase activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160332993A1 (en) * 2014-01-31 2016-11-17 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US20170174713A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences Drive Tank-binding kinase inhibitor compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160332993A1 (en) * 2014-01-31 2016-11-17 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US20170174713A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences Drive Tank-binding kinase inhibitor compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 28 May 2009 (2009-05-28), Database accession no. 28408238 *
DATABASE PubChem 3 September 2007 (2007-09-03), Database accession no. 16722836 *
DATABASE PubChem 30 November 2012 (2012-11-30), Database accession no. 67518325 *

Also Published As

Publication number Publication date
WO2018096525A2 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
WO2020243415A3 (en) Tead inhibitors and uses thereof
MX2020007797A (en) Gcn2 inhibitors and uses thereof.
MX2020007799A (en) Gcn2 inhibitors and uses thereof.
PH12021500026A1 (en) Irak degraders and uses thereof
MX2021014441A (en) Tead inhibitors and uses thereof.
WO2018195397A3 (en) Indole ahr inhibitors and uses thereof
PH12022551524A1 (en) Irak degraders and uses thereof
WO2020084305A9 (en) Bicyclic peptide ligands and uses thereof
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
MX2021004245A (en) Indole ahr inhibitors and uses thereof.
EP3923935A4 (en) Compounds, compositions and methods
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
PH12022551522A1 (en) Smarca degraders and uses thereof
WO2018006074A3 (en) Compounds and methods for modulating rna function
EP4302827A3 (en) Rapamycin analogs and uses thereof
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
EP4488286A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2020001793A (en) Ahr inhibitors and uses thereof.
EP3924341A4 (en) Compounds, compositions and methods
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
EP3880194A4 (en) Deuterated compounds, compositions, and uses
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP4428234A3 (en) Direct-to-library methods, systems, and compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18726022

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018726022

Country of ref document: EP

Effective date: 20201027

122 Ep: pct application non-entry in european phase

Ref document number: 18726022

Country of ref document: EP

Kind code of ref document: A2